Publications by authors named "Michael Reader"

Claim this Profile
C
Correction to "Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)".
James E H Day, Valerio Berdini, Joan Castro, Gianni Chessari, Thomas G Davies, Michael Reader

J Med Chem· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2).
James E H Day, Valerio Berdini, Joan Castro, Gianni Chessari, Thomas G Davies, Michael Reader

J Med Chem· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK.
Joanne M Munck, Valerio Berdini, Luke Bevan, Jessica L Brothwood, Juan Castro, Michael Reader

Mol Cancer Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2.
Tom D Heightman, Valerio Berdini, Luke Bevan, Ildiko M Buck, Maria G Carr, Michael Reader

J Med Chem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660).
Christopher N Johnson, Jong Sook Ahn, Ildiko M Buck, Elisabetta Chiarparin, James E H Day, Michael Reader

J Med Chem· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2.
Tom D Heightman, Valerio Berdini, Hannah Braithwaite, Ildiko M Buck, Megan Cassidy, Michael Reader

J Med Chem· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis and operative management of a perforated de Garengeot hernia.
Alexi Bloom, Flavio E Baio, Keemberly Kim, Joseph S Fernandez-Moure, Michael Reader

Int J Surg Case Rep· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP).
Emiliano Tamanini, Ildiko M Buck, Gianni Chessari, Elisabetta Chiarparin, James E H Day, Michael Reader

J Med Chem· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An unusual presentation of congenital intestinal malrotation in a nonagenarian.
Joseph S Fernandez-Moure, Maya L Moses, Andres Garcia, Michael M Reader

Int J Surg Case Rep· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP.
Gianni Chessari, Ildiko M Buck, James E H Day, Philip J Day, Aman Iqbal, Michael Reader

J Med Chem· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models.
Matthew Squires, George Ward, Gordan Saxty, Valerio Berdini, Anne Cleasby, Michael Reader

Mol Cancer Ther· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of imidazo[1,2-b][1,2,4]triazines as GABA(A) alpha2/3 subtype selective agonists for the treatment of anxiety.
Michael G N Russell, Robert W Carling, Leslie J Street, David J Hallett, Simon Goodacre, Michael Reader

J Med Chem· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis